Peer-based credentialing for brachytherapy: Application in permanent seed implant

PurposeThe purpose of the study was to establish a quantitative method for implant quality evaluation in permanent seed implant brachytherapy for credentialing. Delivery-based credentialing will promote consistency in brachytherapy seed delivery and improve patient outcomes.MethodsA workflow for delivery-based credentialing was outlined and applied to permanent breast seed implant brachytherapy. Delivery simulations were performed on implantable anthropomorphic breast phantoms. Two institutions experienced in permanent seed implant brachytherapy demonstrated the peer credentialing process. Each delivery was evaluated for seed placement accuracy as the measure of implant quality, both for implant accuracy and across five simulations to assess implant variation. Initial credentialing criteria are set based on two factors; the mean seed placement accuracy (implant accuracy) and the mean standard deviation (seed variation) with the threshold for each set with the addition of two standard deviations.ResultsAcross two institutions, seed placement accuracy (±standard deviation) was calculated for all five delivery simulations to yield 6.1 (±2.6) mm. To set credentialing criteria, the implant accuracy (6.1 mm) plus two standard deviations (2.0 mm) and the seed variation (2.6 mm) plus two standard deviations (0.8) mm yield a threshold of 8.1 ± 3.4 mm. It is expected that 95% of experienced institutions would perform the phantom simulation within this threshold.ConclusionBrachytherapy programs should validate delivery accuracy by formal credentialing, which is standard in external beam programs. This quantitative implant evaluation should be combined with current credentialing standards for permanent seed brachytherapy to form a comprehensive validation of institutional brachytherapy program quality.     

Development,implementation, and outcomes of a simulation-based medical education (SBME) prostate brachytherapy workshop for radiation oncology residents

PurposeDespite a preponderance of data demonstrating strong clinical outcomes and cost-effectiveness, prostate brachytherapy use and competency continue to decline. Enhanced resident education may help reverse this trend. We therefore developed and implemented a simulation-based medical education course for low-dose-rate prostate brachytherapy (LDR-PB).Materials and MethodsA 1-week LDR-PB course comprised four 1-h lectures on clinical outcomes, physics, radiobiology, and anatomy/contouring, followed by a 4.5-h simulation session on ultrasound-guided prostate phantom implantation, was developed for radiation oncology residents at an academic institution. A 10-statement Likert-scale survey and 20-question multiple-choice test were administered 1 week before and 4 weeks after the course.ResultsPrecourse and postcourse instruments were completed by 24 and 20 residents, respectively. The median number of prior LDR-PB cases after at least one genitourinary rotation was 10.5 (range 5–20). Overall mean test scores were significantly improved (55% before the course vs 68% after the course; p = 0.010). Mean Likert scores significantly increased on nine of 10 survey statements and were significantly increased overall (2.4 before the course vs 3.3 after the course, p < 0.001). When asked about interest in performing brachytherapy after residency, 37.5% of residents “agreed” or “strongly agreed” before the course vs 50% after the course (p = 0.41). Those with higher postresidency brachytherapy interest (scores of 4–5 vs 1–3) had significantly more LDR-PB cases (11.2 vs 5.3 cases; p = 0.005).ConclusionsA 1-week simulation-based medical education course for LDR-PB can improve didactic performance and self-reported technical competence/confidence, and may increase overall enthusiasm for brachytherapy. Future studies at our institution will incorporate evaluation of implant quality and assessment of procedural competence into this framework. Residency programs should dedicate resources to this essential component of radiation oncology.     

Development and characterization of an anthropomorphic breast phantom for permanent breast seed implant brachytherapy credentialing

PurposeTo develop an anthropomorphic breast phantom for use in credentialing of permanent breast seed implant brachytherapy.Methods and MaterialsA representative external contour and target volume was used as the basis of mold manufacturing for anthropomorphic breast phantom development. Both target and normal tissue were composed of gel-like materials that provide suitable computed tomography and ultrasound contrast for brachytherapy delivery. The phantoms were evaluated for consistency in construction (target location) and Hounsfield unit (computed tomography contrast). For both target and normal tissue, the speed of sound was measured and compared to the image reconstruction algorithm's expectation value. Five phantoms were imaged preimplant and postimplant to assess interphantom similarity as well as to evaluate the uncertainty in quantifying seed position.ResultsThe average Hounsfield units of the target and normal tissue gels is −146 ± 5 and 23 ± 1, respectively. The average speed of sound of the target and normal tissue gels is 1485 ± 7 m/s and 1558 ± 9 m/s, respectively, resulting in an estimated 0.4 mm uncertainty in image guidance. The registration/deformation uncertainty was determined to be 0.8 mm. The standard combined uncertainty in assessing seed position spatial accuracy, also including a 0.9 mm estimate based on literature for seed localization, is estimated to be 1.3 mm.ConclusionsThe development of the anthropomorphic breast phantom and evaluation of both the consistency as well as overall seed position uncertainty illustrates the suitability of this phantom for use in brachytherapy end-to-end delivery and implant accuracy evaluation. When evaluating a user's implant accuracy, we estimate a standard combined uncertainty of 1.3 mm.     

Treatment planning considerations for permanent breast seed implant

PurposeTo determine an optimal planning strategy for permanent breast seed implant that minimizes dose heterogeneity without degrading coverage and conformity.Methods and MaterialsA simple model was developed to investigate planning strategies incorporating a range of ¹⁰³Pd seed activities, needle and seed spacings, and implants in which seed positions are either restricted to or permitted outside of spherical planning target volumes (PTVs). To address more realistic target geometries, model parameters were used to retrospectively replan a 10-patient cohort in MIM Symphony.ResultsWe confirm that the current clinical modified uniform implantation pattern provides the most favorable dose distributions, given the resolution of the template grid and spacer length. We show that needle and seed counts for replans with seed placement permitted 0.3 cm outside of the PTV are most comparable to clinical preplans, but offer a 13 ± 11% average reduction in the V_PTV150%. Replans produced with seed placement 0.5 cm outside of the PTV provide the largest improvement in dose homogeneity, at the cost of a slight increase in irradiated volume and an increase in the number of needles and seeds.ConclusionsImplanting seeds beyond the PTV within a 0.3–0.5 cm margin, and optimizing seed activity on a per patient basis, allows for improvement in dose homogeneity. However, these plans require higher needle and seed counts and result in a small increase in irradiated volume. Before planning recommendations can be made, the implications of these changes must be investigated in the context of clinical outcome for permanent breast seed implant.     

Reducing seed migration to near zero with stranded-seed implants: Comparison of seed migration rates to the chest in 1000 permanent prostate brachytherapy patients undergoing implants with loose or stranded seeds

PurposePulmonary seed emboli to the chest may occur after permanent prostate brachytherapy (PPB). The purpose of this study is to analyze factors associated with seed migration to the chest in a large series of PPB patients from a single institution undergoing implant with either loose seeds (LS), mixed loose and stranded seeds (MS), or exclusively stranded seeds in an absorbable vicryl suture (VS).Methods and MaterialsBetween May 1998 and July 2015, a total of 1000 consecutive PPB patients with postoperative diagnostic chest x-rays at 4 months after implant were analyzed for seed migration. Patients were grouped based on seed implant technique: LS = 391 (39.1%), MS = 43 (4.3%), or VS = 566 (56.6%). Univariate and multivariate analysis were performed using Cox proportional hazards regression models to determine predictors of seed migration.ResultsOverall, 18.8% of patients experienced seed migration to the chest. The incidence of seed migration per patient was 45.5%, 11.6%, and 0.9% (p < 0.0001), for patients receiving LS, MS, or VS PPB, respectively. The right and left lower lobes were the most frequent sites of pulmonary seed migration. On multivariable analysis, planimetry volume (p = 0.0002; HR = 0.7 per 10 cc [0.6–0.8]), number of seeds implanted (p < 0.0001, HR = 2.4 per 25 seeds [1.7–3.4]), LS implant (p < 0.0001, HR = 15.9 [5.9–42.1]), and MS implant (p = 0.001, HR = 7.9 [2.3–28.1]) were associated with seed migration to the chest.ConclusionsIn this large series, significantly higher rates of seed migration to the chest are observed in implants using any LS with observed hazard ratios of 15.9 and 7.9 for LS and MS respectively, as compared with implants using solely stranded seeds.     

Implementing a simulation-based curriculum for hybrid intracavitary/interstitial brachytherapy using a new,commercially available,US/MR/CT-compatible gynecologic phantom

PURPOSETo establish a simulation-based workshop for teaching hybrid intracavitary/interstitial (IC/IS) brachytherapy skills using a new, commercially available US/CT/MRI-compatible gynecologic phantom prototype.METHODS AND MATERIALSThe VIOMERSE gynecological trainer phantom consisted of tissue-like colloid material and was US, CT, and MRI-compatible. We designed a hands-on workshop incorporating the phantom prototype to teach skills for hybrid IC/IS brachytherapy including pre-implant planning, procedural steps of implant placement, and post-implant evaluation. The workshop impact was evaluated with pre- and post-workshop surveys and responses were analyzed with Wilcoxon matched-pairs signed-rank test.RESULTSThirteen residents, divided into small groups, attended one of three separate 1-h workshop sessions held during the gynecologic education block. Workshop steps included IC applicator placement, tumor mapping and pre-planning desired location and depth of needles for hybrid IC/IS application, IS needle labelling and insertion, image review of needle placements, comparison of IC-alone versus IC/IS brachytherapy plans. Responses to questions ascertaining knowledge, confidence, and ability in planning and executing hybrid IC/IS procedures all demonstrated significant improvement from pre- to post-workshop. In response to whether the session was an effective learning experience, all residents rated the workshop with a score of 9 (n = 1) or 10 (n = 12) out of 10, with a score of 10 indicating “strongly agree.”CONCLUSIONSImplementation of a hybrid IC/IS brachytherapy workshop utilizing a new, commercially-available phantom prototype was successful, with clear, subjective benefit for the residents in our program. This experience may inform continued efforts towards standardizing brachytherapy curricula across programs and increasing trainee exposure to interstitial procedures.     

Dosimetric consequences of seed placement accuracy in permanent breast seed implant brachytherapy

PurposeThis study quantifies the dosimetric impact of implant accuracy and derives a quantitative relationship relating implant accuracy to target dosimetry.Methods and MaterialsA framework was developed to simulate multiple implants for error combinations. Spherical clinical target volumes (CTVs) were modeled with volumes 1.4 cm³, 9.2 cm³, and 20.6 cm³, representing the range seen clinically. Each CTV was expanded 10 mm isotropically to create a planning target volume (PTV).. Random and systematic seed placement errors were simulated by shifting needles from their planned positions. Implant errors were simulated over the range of clinically practical errors in permanent breast seed implant. The relative effect on target coverage was evaluated. Regression analysis was performed to derive relationships between CTV dosimetry and the magnitude of implant accuracy. The validity of the clinically used 10 mm PTV margin for each of the CTVs was assessed.ResultsIntroducing practical implant errors resulted in CTV V_90% median (10th and 90th percentile) of 97.7% (85.9% and 100%), 96.2% (86.8% and 99.7%), and 100% (77.8% and 100%) for the typical, large, and small CTV, respectively. All CTVs show similar trends in target coverage. Polynomials were derived relating seed placement accuracy to median (R² = 0.82) and 10th percentile (R² = 0.78) CTV V_90%._.ConclusionsThis work quantitatively describes the relationship between implant accuracy and CTV coverage. Based on simulations, the 10 mm PTV margin is adequate to maintain target coverage. These equations can be used with institutional seed placement accuracy to estimate coverage.     

Impact of small prostate size on postimplant prostate dosimetry: Analysis of a large community database

PurposeAchieving high-quality permanent interstitial brachytherapy in smaller prostates is thought to be more difficult than in larger glands. This study evaluates 4547 implants in a large community database to test this hypothesis.Methods and MaterialsFrom January 2003 to October 2010, 4547 prostate brachytherapy implants from a large community database were analyzed. The cohort was divided into three groups based on size, namely smaller (<30 cm³, n = 1301), medium (30–40 cm³, n = 1861), and large (>40 cm³, n = 1385). Postimplant dosimetry, including D₉₀, V₁₀₀, and V₁₀₀ by prostate sector, was performed for each implant. Comparison of mean V₁₀₀ among small, medium, and larger prostate volume cohorts was performed using a one-way analysis of variance test.ResultsFor the overall cohort, the D₉₀ was 105% and 104% for monotherapy and boost, respectively. Mean D₉₀ for small prostates was 106% and 104% for monotherapy and boost, respectively. Mean V₁₀₀ for small prostates was 91.1% and 90.0%, respectively. Coverage for small prostates was as good or slightly better than larger glands. V₁₀₀ by prostate sector revealed that there were no sectors for which smaller glands had significantly inferior coverage compared with larger glands.ConclusionAlthough smaller prostates may in some respects be more technically difficult to implant than larger glands, a review of community-based brachytherapists reveals that with current implant techniques, good quality implants are readily achievable in men with smaller glands.     

Appropriate timing for postimplant imaging in permanent breast seed implant: Results from a serial CT study

PurposePostimplant analysis in permanent breast seed implant (PBSI) is performed at inconsistent times subsequent to seed implantation across cancer centers, creating challenges in the interpretation of dosimetric data and ultimately the correlation with clinical outcomes. The purpose of this study is to determine the most appropriate time postimplant to perform this analysis.Methods and MaterialsNine patients treated at our institution with PBSI were included in this analysis. Each underwent 4 postimplant CT scans: 0, 15, 30, and 60 days postimplant. A model of the accumulated dose was created by deformably registering the Day 15, 30, and 60 postimplant CT scans and dose matrices to the Day 0 scan, scaling for seed decay. The results from this model were compared to each individual postplan by integral comparison of dose–volume histogram curves for a dose evaluation volume.ResultsThe Day 30 postplan showed the best agreement with the accumulated dose model and the smallest interpatient variability across the patient cohort. The mean (±SD) for the dose evaluation volume V₉₀, V₁₀₀, V₁₅₀, and V₂₀₀ for the accumulated dose model was 90 ± 7%, 86 ± 8%, 66 ± 14%, and 41 ± 16%, respectively.ConclusionsBased on the results of this patient cohort, we recommend that postimplant dosimetric analysis for PBSI be performed approximately 30 days following the implant.     

Sector analysis of dosimetry of prostate cancer patients treated with low-dose-rate brachytherapy

PurposeBrachytherapy is an effective single treatment modality for low- and intermediate-risk prostate cancer. Here, we compare the radiation doses in different prostate sectors between the preimplant planning images and the postimplant dosimetry.Methods and MaterialsTwo hundred fifteen consecutive patients treated for prostate cancer by ¹²⁵I seed brachytherapy were assessed. Pretreatment plans using transrectal ultrasound images of the prostate were compared with the dose calculated on posttreatment MRI and CT scans obtained 1 month after seed implantation. Twelve sectors were generated by dividing the prostate base, midgland, and apex into four quadrants each. Pretreatment and posttreatment dosimetry were compared between the 12 different sectors of the prostate.ResultsAverage V₁₀₀ (percentage of prostate volume that receives 100% of the prescribed dose) in the preimplant planning images of the prostate was 99.9 ± 0.25% compared with postimplant V₁₀₀ of 94.8 ± 3.77% (p < 0.0001). Prostate V₁₀₀ in the postimplant dosimetry was >91% in all sectors, except the anterior base sector, in which it was 64.87 ± 20.96%. Average 1-month D₉₀ (the dose to 90% of the prostate volume) was 114.5 ± 10.55%. D₉₀ at 1 month compared with preimplant planning was lower in the prostate base and higher in the prostate apex (p < 0.001).ConclusionsOur results show that in ¹²⁵I seed brachytherapy, prostate base receives a lower dose and apex receives a higher dose compared with preimplant planned dose coverage.     

Novel use of ViewRay MRI guidance for high-dose-rate brachytherapy in the treatment of cervical cancer

PurposeTo characterize image quality and feasibility of using ViewRay MRI (VR)–guided brachytherapy planning for cervical cancer.Methods and MaterialsCervical cancer patients receiving intracavitary brachytherapy with tandem and ovoids, planned using 0.35T VR MRI at our institution, were included in this series. The high-risk clinical target volume (HR-CTV), visible gross tumor volume, bladder, sigmoid, bowel, and rectum contours for each fraction of brachytherapy were evaluated for dosimetric parameters. Typically, five brachytherapy treatments were planned using the T2 sequence on diagnostic MRI for the first and third fractions, and a noncontrast true fast imaging with steady-state precession sequence on VR or CT scan for the remaining fractions. Most patients received 5.5 Gy × 5 fractions using high-dose-rate Ir-192 following 45 Gy of whole-pelvis radiotherapy. The plan was initiated at 5.5 Gy to point A and subsequently optimized and prescribed to the HR-CTV. The goal equivalent dose in 2 Gy fractions for the combined external beam and brachytherapy dose was 85 Gy. Soft-tissue visualization using contrast-to-noise ratios to distinguish normal tissues from tumor at their interface was compared between diagnostic MRI, CT, and VR.ResultsOne hundred and forty-two fractions of intracavitary brachytherapy were performed from April 2015 to January 2017 on 29 cervical cancer patients, ranging from stages IB1 to IVA. The median HR-CTV was 27.78 cc, with median D₉₀ HR-CTV of 6.1 Gy. The median time from instrument placement to start of treatment using VR was 65 min (scan time 2 min), compared to 105 min using diagnostic MRI (scan time 11 min) (t-test, p < 0.01). The contrast-to-noise ratio of tumor to cervix in both diagnostic MRI and VR had significantly higher values compared to CT (ANOVA and t-tests, p < 0.01).ConclusionsWe report the first clinical use of VR-guided brachytherapy. Time to treatment using this approach was shorter compared to diagnostic MRI. VR also provided significant advantage in visualizing the tumor and cervix compared to CT. This presents a feasible and reliable manner to image and plan gynecologic brachytherapy.     

Seed migration in prostate brachytherapy depends on experience and technique

PurposeTo determine seed loss and pulmonary migration rate over time in permanent seed prostate brachytherapy.Methods and MaterialsWe analyzed the first 495 patients treated in our department. All patients were treated with loose ¹²⁵I seeds with automated seed delivery system and real-time intraoperative planning. Pelvic fluoroscopic imaging was done 30 days after the implant. Patients were divided into five groups of 100 patients according to the order they were treated, and groups were compared using χ² test and one-way analysis of variance.ResultsA total of 22.8% of patients lost at least one seed. The highest percentage of patients losing any number of seeds was in the first 100. Thirty-eight percent lost at least one seed. This number decreased gradually and was only 9% in Patients 400–499. The mean total seed loss rate (number of seeds lost/number seeds implanted) changed significantly over time (p < 0.001). There was a continuous significant (p < 0.001) decline after the first 100 patients (1.25% for the first 100 patients) followed by a rise in Patients 300–399, followed by another decline (0.21% for the last 100 patients). The seed loss rate to the thorax changed significantly over time (p = 0.009). It rose after an initial rate of 0.25–0.42% in Patients 200–299 and 300–399 and declined later to a rate of 0.21% in the last 100 patients.ConclusionsWe found a learning curve for seed migration. Avoiding implanting seeds outside of the capsule and modern transrectal ultrasound imaging can help decrease migration.     

Placement of an absorbable rectal hydrogel spacer in patients undergoing low-dose-rate brachytherapy with palladium-103

PurposeRates of rectal toxicity after low-dose-rate (LDR) brachytherapy for prostate cancer are dependent on rectal dose, which is associated with rectal distance from prostate and implanted seeds. Placement of a hydrogel spacer between the prostate and rectum has proven to reduce the volume of the rectum exposed to higher radiation dose levels in the setting of external beam radiotherapy. We present our findings with placing a rectal hydrogel spacer in patients following LDR brachytherapy, and we further assess the impact of this placement on dosimetry and acute rectal toxicity.Methods and MaterialsBetween January 2016 and April 2017, 74 patients had placement of a hydrogel spacer, immediately following a Pd-103 seed-implant procedure. Brachytherapy was delivered as follows: as a monotherapy to 26 (35%) patients; as part of planned combination therapy with external beam radiotherapy to 40 (54%) patients; or as a salvage monotherapy to eight (11%) patients. Postoperative MRI was used to assess separation achieved with rectal spacer. Acute toxicity was assessed retrospectively using Radiation Oncology Therapy Group radiation toxicity grading system. Rectal dosimetry was compared with a consecutive cohort of 136 patients treated with seed implantation at our institution without a spacer, using a 2-tailed paired Student's t test (p < 0.05 for statistical significance).ResultsOn average, 11.2-mm (SD 3.3) separation was achieved between the prostate and the rectum. The resultant mean rectal volume receiving 100% of prescribed dose (V_100%), dose to 1 cc of rectum (D_1cc), and dose to 2 cc of rectum (D_2cc) were 0 (SD 0.05 cc), 25.3% (SD 12.7), and 20.5% (SD 9.9), respectively. All rectal dosimetric parameters improved significantly for the cohort with spacer placement as compared with the nonspacer cohort. Mean prostate volume, prostate V₁₀₀ and dose to 90% of gland (D₉₀) were 29.3 cc (SD 12.4), 94.0% (SD 3.81), and 112.4% (SD 12.0), respectively. Urethral D₂₀, D_5cc, and D_1cc were 122.0% (SD 17.27), 133.8% (SD 22.8), and 144.0% (SD 25.4), respectively. After completing all treatments, at the time of first the followup, 7 patients reported acute rectal toxicity—6 experiencing Grade 1 rectal discomfort and 1 (with preexisting hemorrhoids) experiencing Grade 1 bleeding.ConclusionsInjection of rectal spacer is feasible in the post-LDR brachytherapy setting and reduces dose to the rectum with minimal toxicity. Prostate and urethral dosimetries do not appear to be affected by the placement of a spacer. Further studies with long-term followup are warranted to assess the impact on reduction of late rectal toxicity.     

Conventional vs machine learning–based treatment planning in prostate brachytherapy: Results of a Phase I randomized controlled trial

PurposeThe purpose of this study was to evaluate the noninferiority of Day 30 dosimetry between a machine learning–based treatment planning system for prostate low-dose-rate (LDR) brachytherapy and the conventional, manual planning technique. As a secondary objective, the impact of planning technique on clinical workflow efficiency was also evaluated.Materials and Methods41 consecutive patients who underwent I-125 LDR monotherapy for low- and intermediate-risk prostate cancer were accrued into this single-institution study between 2017 and 2018. Patients were 1:1 randomized to receive treatment planning using a machine learning–based prostate implant planning algorithm (PIPA system) or conventional, manual technique. Treatment plan modifications by the radiation oncologist were evaluated by computing the Dice coefficient of the prostate V_150% isodose volume between either the PIPA—or conventional—and final approved plans. Additional evaluations between groups evaluated the total planning time and dosimetric outcomes at preimplant and Day 30.Results21 and 20 patients were treated using the PIPA and conventional techniques, respectively. No significant differences were observed in preimplant or Day 30 prostate D_90%, V_100%, rectum V₁₀₀, or rectum D_1cc between PIPA and conventional techniques. Although the PIPA group had a larger proportion of patients with plans requiring no modifications (Dice = 1.00), there was no significant difference between the magnitude of modifications between each arm. There was a large significant advantage in mean planning time for the PIPA arm (2.38 ± 0.96 min) compared with the conventional (43.13 ± 58.70 min) technique (p >> 0.05).ConclusionsA machine learning–based planning workflow for prostate LDR brachytherapy has the potential to offer significant time savings and operational efficiencies, while producing noninferior postoperative dosimetry to that of expert, conventional treatment planners.     

Characterization of implant displacement and deformation in gynecologic interstitial brachytherapy

PurposeTo determine the uncertainties in implant position during multifraction gynecologic interstitial brachytherapy, we analyzed the interfraction displacements and deformations of gynecologic interstitial implants.Methods and MaterialsFourteen gynecologic patients treated with multifraction high-dose-rate interstitial brachytherapy received two CT scans each at the time of implantation and 48–72 h later. Rigid fusions on the pubic symphysis were performed. This analysis included catheter shifts in the cranial (CR), caudal (CA), anterior, posterior, left, and right directions; template shifts; the change in the catheter length measured along the path from catheter tip to catheter connector (offset); the change in relative distances between catheters (deformations); and changes in rectum and bladder D_2cc and tumor D₉₀.ResultsOf the 198 catheters analyzed, the number of catheter shifts (%) and mean ± standard deviation were 43% CA (5.0 ± 2.0 mm), 22% CR (7.9 ± 4.0 mm), 14% anterior (6.3 ± 2.1 mm), 48% posterior (8.7 ± 3.1 mm), 7% left (4.8 ± 0.4 mm), and 9% right (5.4 ± 0.9 mm). Catheter offsets were 3% CA (7.2 ± 6.3 mm) and 11% CR (6.1 ± 2.6 mm). Template shifts were 43% CA (5.2 ± 1.6 mm) and 14% CR (6.6 ± 4.0 mm). Deformations were 10 shrinkages (4.7 ± 0.9 mm) and 32 expansions (4.7 ± 0.5 mm). Dosimetric changes were 5.2% ± 10.8% for rectum D_2cc, −1.1% ± 18.5% for bladder D_2cc, and −5.1% ± 6.7% for tumor D₉₀.ConclusionsOn average, less than 1 cm displacements and deformations of the implant occurred over the course of treatment. Proper quality assurance methodologies should be in place to detect shifts that can potentially result in inadvertent insertion into normal tissue.     

Automated air kerma strength quality assurance of permanent seed implant prostate brachytherapy sources using vendor autoradiographs

PurposeTo develop a novel quality assurance (QA) program to determine the air kerma strength (AKS) of brachytherapy seeds within preloaded needles using autoradiographs alone, without jeopardizing sterility or necessitating procedural changes either by the vendor or in the operating room.Methods and MaterialsDigital autoradiographs of QA seed orders and sterile preloaded needles were acquired. Regions of interest of each preloaded seed were determined through an iterative scanning process identifying changes from background levels to radioactivity exposure. Average exposure values through the center of each region of interest were fitted with a Gaussian curve and Full Width at Half Maximums (FWHMs) were calculated. The two-dimensional exposure-scaled FWHM (Exp_2D) measurements for the QA seed orders were plotted against measured AKS values and related using a linear curve fit that was adjusted using the third-party assay average AKS and applied as a calibration curve to convert Exp_2D to AKS.ResultsEstimated seed AKS was found to have a strong dependence on position within the holding tray because of imager positioning inconsistencies. Calculated seed AKS for patient-specific seed orders using the curve scaling factor varied from the nominal order AKS by 1.1 ± 0.9% and from the third-party assay measurements by 0.0 ± 0.4%.ConclusionsThis work depicts a clinically useful tool to aid in QA of preloaded brachytherapy permanent seed implant needles without compromising sterility or increasing clinical workloads. With this procedure, each individual seed's AKS can be verified automatically before a patient's scheduled implant or retroactively when auditing patient records.     

Simulation-based graduate medical education in MR-guided brachytherapy for cervical cancer

PurposeBrachytherapy is critical for the curative treatment of locally advanced cervical cancer. Although brachytherapy use is declining in the United States (U.S.), novel interstitial or intracavitary applicators and advances in image guidance for applicator placement and treatment planning have allowed for tumor dose escalation while reducing normal tissue toxicity. Recent survey data have suggested insufficient brachytherapy training for radiation oncology trainees in the United States. This study aimed to address these gaps by developing and piloting a simulation-based education (SBE) workshop for MR-guided cervical cancer brachytherapy.Methods and MaterialsAn SBE workshop was developed for graduate medical education (GME) trainees focusing on MR-guided brachytherapy for cervical cancer. Four hands-on stations, simulating aspects of the procedure, were led by a team of gynecological brachytherapy experts. The learners were radiation oncology residents and fellows in a U.S. GME training program. The primary outcome was feasibility, assessed by completion of the workshop within the time constraints of the curriculum. Learners completed preworkshop and postworkshop surveys to provide information on efficacy.ResultsThe workshop was successfully completed in a 1-h block of GME didactic time. Ten trainees completed all four stations, and all completed preworkshop and postworkshop surveys, which showed improvements in knowledge and technical proficiency. Feedback was positive, and trainees requested additional learning opportunities.ConclusionsThis study showed that GME-focused SBE in MR-guided cervical cancer brachytherapy was feasible. SBE provided a nonclinical environment in which to practice aspects of MR-guided brachytherapy. Ongoing work includes collaboration with other U.S. institutions. Future studies should focus on international adaptation.